Physician profile
Happy Verma
NPI 1336249184
$413.96
in general payments reported to CMS, 2019-2025
12 companies · $34.64 in 2025
The $34.64 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.43 · 2022: $72.42 · 2023: $92.16 · 2024: $196 · 2025: $34.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $102.29 | 2024 | |
| Abbvie INC. | $68.55 | 2022-2024 | Ubrelvy |
| Amgen INC. | $38.29 | 2023-2024 | Repatha, Otezla |
| Medtronic, INC. | $34.64 | 2025 | Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.71 | 2024 | Xifaxan |
| Lilly USA, LLC | $26.64 | 2023 | Jardiance |
| Corium, LLC | $20.33 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.19 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.43 | 2019 | |
| Merck Sharp & Dohme LLC | $18.29 | 2023 | Steglatro, Verquvo, Belsomra |
| Xeris Pharmaceuticals, INC. | $16.89 | 2024 | Gvoke Hypopen |
| Novo Nordisk INC | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Happy Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.